Symptom Control During Chemotherapy (SCDC)

MN Community Measurement

MN Community Measurement

- Nonprofit health care quality improvement and reporting organization
- Specialize in developing, collecting, analyzing and publicly reporting information on health care quality and cost
- Founded in 2005
- Multi-stakeholder collaborative – physicians, hospitals and health systems, health plans, employers, consumers and state government

© 2018 MN Community Measurement. All Rights Reserved.

MN Community MEASUREMENT
Measure Up To Better Health

Measure Background

- **4 new measures** related to Symptom Control During Chemotherapy (SCDC) using patient-report outcome tool
  - Symptom severity assessment using PRO-CTCAE tool (Process)
  - Symptom control – Pain severity (Outcome)
  - Symptom control – Nausea severity (Outcome)
  - Symptom control – Constipation severity (Outcome)

- Pilot-tested by oncology practices in Minnesota

© 2018 MN Community Measurement. All Rights Reserved.

Benefits of Measurement and Reporting



MN Community Measurement
Measure Up To Better Health

© 2018 MN Community Measurement. All Rights Reserved.

Steps to take now

Reporting will begin in the 2020 report year using 2019 dates of service. Here are steps to take in preparation for reporting:

- ✓ Implement the **Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) tool** (prior to January 1, 2019)

- ✓ Download the tool and terms of use along with other resources available on MNCM's Data Portal

- ✓ Notify MNCM about plans to implement and report these measures

  support@mncm.org

  (612) 746-4522

© 2018 MN Community Measurement. All Rights Reserved.

Agenda

1. Data Submission Timeline
2. Denominator Identification
3. Numerator Identification
4. Validation Steps
5. Resources

© 2018 MN Community Measurement. All Rights Reserved.

Timelines



2020 Report Year
(2019 Dates of Service)

Submission activity	Date range
Dates of service	Jan 1, 2019 – Dec 31, 2019
Data submission	Beginning of April 2020 – Mid-May 2020*
Data validation (quality checks & audits)	April 2020 – July 2020*
Final Results	August/September 2020*

*Subject to change

© 2018 MN Community Measurement. All Rights Reserved.

Denominator



*Patients must be 18 years or older at the beginning of the index period

© 2018 MN Community Measurement. All Rights Reserved.

MN Community MEASUREMENT
Measure Up To Better Health

Value Sets

Currently found in Appendix C of the Data Collection guide

Table 1: Chemotherapy Biologic Value Set

CPT	CPT Description
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic
96409	intravenous, push technique, single or initial substance/drug
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance/ drug
96416	Initiation of prolonged chemotherapy infusion (> 8 hours) requiring portable or implantable pump
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
96405	Chemotherapy administration, intralesional
96420	Chemotherapy administration, intra-arterial push
96422	Chemotherapy administration, intra-arterial infusion
96425	Intra-arterial pump initiation
96440	Chemo admin into pleural cavity
96446	Chemo admin into peritoneal cavity
96450	Chemo admin into CNS
96542	Chemo admin via subcutaneous reservoir
ICD-10	**ICD-10 Code Description**
Z51.11	Encounter for antineoplastic chemotherapy
Z51.12	Encounter for antineoplastic immunotherapy

Remember: These should only be found using Oncology as the specialty

Note: ICD10 codes updated August 2018

© 2018 MN Community Measurement. All Rights Reserved.

MN Community MEASUREMENT
Measure Up To Better Health

Index and Assessment Period



2019 Dates of Service

Index period: occurs when the patient begins a new regimen of chemotherapy and/or biologic immunotherapy and all of the following criteria are met:

- ✓ Cycle 1 Day 1 occurs between **1/1/2019 – 6/30/2019**
- ✓ Administration of chemo and/or biologic is billed by specific CPT codes (*Chemotherapy Biologic* Value Set)

Assessment period: for patients who meet the index criteria, the assessment period allows enough time for the completion of three cycles of chemotherapy for each patient by the end of the 2019 calendar year

© 2018 MN Community Measurement. All Rights Reserved.

Denominators



Note: The Portal identifies which of the additional cycles a patient is eligible for.

© 2018 MN Community Measurement. All Rights Reserved.

MN Community Measurement
Measure Up To Better Health

Denominator Example #1

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 5/24/2019
- **Cycle 2 Day 1 date:** 6/10/2019
- **Cycle 3 Day 1 date:** [blank]
  Patient did not continue treatment after finishing Cycle 2

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **No** → The patient did not have a Cycle 3 Day 1 because they discontinued treatment after Cycle 2

© 2018 MN Community Measurement. All Rights Reserved.

Denominator Example #2

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 3/31/2019
- **Cycle 2 Day 1 date:** 4/13/2019
- **Cycle 3 Day 1 date:** 5/1/2019, but discontinued treatment before end of cycle

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **Yes** → Because the patient had a Cycle 3 Day 1 between 1/1/2019 – 12/31/2019 (assessment period), they would still be eligible for the measure, despite dropping out before the end of the cycle

© 2018 MN Community Measurement. All Rights Reserved.

Denominator Example #3

An eligible patient had the following treatment regimen:

- **Cycle 1 Day 1 date:** 6/29/2019
- **Cycle 2 Day 1 date:** 7/15/2019
- **Cycle 3 Day 1 date:** 8/2/2019

Which of the cycle denominators would the patient be eligible for?

Cycle 1: **Yes** → Cycle 1 Day 1 occurred between 1/1/2019 - 6/30/2019 (index period)

Cycle 2: **Yes** → Cycle 2 Day 1 occurred between 1/1/2019 - 12/31/2019 (assessment period)

Cycle 3: **Yes** → Cycle 3 Day 1 occurred between 1/1/2019 – 12/31/2019 (assessment period)

© 2018 MN Community Measurement. All Rights Reserved.

Patient Scenario #1

A 55 year old female with Stage 3 breast cancer was started on a regimen of anthracycline/cyclophosphamide chemotherapy every 21 days for 4 cycles via IV infusion as ordered by her oncologist. Her first day of her first cycle began on 2/15/19. Administration of the therapy is billed under CPT code 96413.

Should this patient be included in the denominator? **Yes**

Eligible patient criteria

- ✓ At least 18 years of age
- ✓ Receiving chemotherapy/biologic immunotherapy
- ✓ Cycle 1 Day 1 began between 1/1/2019 – 6/30/2019
- ✓ Seen by oncology specialty
- ✓ CPT/ICD10 code found in *Chemotherapy Biologic* Value Set

© 2018 MN Community Measurement. All Rights Reserved.

MN Community MEASUREMENT
Measure Up To Better Health

Patient Scenario #2

A 32 year old male with Crohn's Disease was started on a biologic treatment regimen on 7/2/2019. His gastroenterologist ordered Infliximab to be given via IV infusion every 8 weeks. Administration of the therapy is billed using CPT code 96413.

Should this patient be included in the denominator? **No**

Eligible patient criteria

- ✓ At least 18 years of age
- ✓ Receiving chemotherapy/biologic immunotherapy
- ✘ Cycle 1 Day 1 began between 1/1/2019 – 6/30/2019
- ✘ Seen by oncology specialty
- ✓ CPT/ICD10 code found in *Chemotherapy Biologic* Value Set

© 2018 MN Community Measurement. All Rights Reserved.

Measures



© 2018 MN Community Measurement. All Rights Reserved.

Measure 1: Symptom Severity Assessment

Process Measure



Interpretation: % of eligible patients for whom a symptom severity assessment was completed during Days 5 – 15 of the cycle using the PRO-CTCAE tool

*Each cycle contributes to the measure numerator (S1, S2, S3)

© 2018 MN Community Measurement. All Rights Reserved.

Measure 2: Pain

Outcome Measure Example



Interpretation: % of eligible patients whose **pain** severity was none or mild during Days 5 – 15 of the cycle

© 2018 MN Community Measurement. All Rights Reserved.

Pre-Submission

- Must be completed and approved by MNCM before data submission

  See Data Submission webinar available on the MNCM Data Portal for more information

- Required information to be shown/explained in screenshots, source code and/or narrative:
  - ✓ **Eligible specialty**
    - What specialty?
    - How is this identified?
  - ✓ **Eligible patient age**
    - What is the age range being used?
    - How will you query this information?
  - ✓ **Chemotherapy CPT/ICD10 codes**
    - Which codes will be used? **List ALL codes!**
  - ✓ **Index/assessment date ranges**
    - What is the date range that will be used to identify patients who meet index criteria?
    - What is the date range that will be used for the assessment period?

© 2018 MN Community Measurement. All Rights Reserved.

Validation

- All groups will be audited during the first report year (2020)
- 30 charts will be randomly selected for review
- Review first 8 charts
  - If no errors, audit is complete
  - If errors, additional 22 charts will be reviewed
- Passing score = 90%

For more information, please review the Data Validation webinar available in the Resources tab in the MNCM Data Portal.

© 2018 MN Community Measurement. All Rights Reserved.

Resources

© 2018 MN Community Measurement. All Rights Reserved.

Frequently Asked Questions

Q: Should we include hospital-based chemotherapy administration?

A: *Similar to our other measures, the intent of the measure is to only include patients seen in an outpatient setting based on chemotherapy administration CPT codes. However, if there is an hospital-based outpatient site within your hospital (e.g. infusion center), those patients should be included.*

Q: Will MDH include this measure in the 2019 reporting rule?

A: *In general, MDH has stated that they expect no major changes to required measures for the 2019 report year. MDH is aware of this measure and MNCM will be encouraging their consideration for future inclusion.*

© 2018 MN Community Measurement. All Rights Reserved.

Contact

Questions?

support@mncm.org

612-746-4522

MN Community MEASUREMENT
Measure Up To Better Health

Connect with us!

On the web
MNCM.org
MNHealthScores.org

On social media
@mnhealthscores
facebook.com/mnhealthscores
Linkedin.com/company/mn-community-measurement

Webpages to Bookmark

- **MNCM Data Portal**
  https://data.mncm.org/login
- **MNCM Corporate Website**
  www.mncm.org
- **MNCM Consumer Website**
  www.mnhealthscores.org

© 2018 MN Community Measurement. All Rights Reserved.

MN Community MEASUREMENT
Measure Up To Better Health